Qingdao Haier BiomedicalLtd Management

Management criteria checks 3/4

Qingdao Haier BiomedicalLtd's CEO is Zhanjie Liu, appointed in Oct 2005, has a tenure of 18.58 years. directly owns 0.02% of the company’s shares, worth CN¥2.31M. The average tenure of the management team and the board of directors is 5.3 years and 5.8 years respectively.

Key information

Zhanjie Liu

Chief executive officer

CN¥2.5m

Total compensation

CEO salary percentage	n/a
CEO tenure	18.6yrs
CEO ownership	0.02%
Management average tenure	5.3yrs
Board average tenure	5.8yrs

Recent management updates

Recent updates

Further Upside For Qingdao Haier Biomedical Co.,Ltd (SHSE:688139) Shares Could Introduce Price Risks After 33% Bounce

Apr 26

Further Upside For Qingdao Haier Biomedical Co.,Ltd (SHSE:688139) Shares Could Introduce Price Risks After 33% Bounce

Apr 26

CEO

Zhanjie Liu (53 yo)

18.6yrs

Tenure

CN¥2,466,900

Compensation

Dr. Zhanjie Liu is General Manager & Director of Qingdao Haier Biomedical Co., Ltd from October 2005.

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Zhanjie Liu	GM & Director	18.6yrs	CN¥2.47m	0.020% CN¥ 2.3m
Ruijuan Mo	Chief Financial Officer	5.3yrs	CN¥1.40m	0.0044% CN¥ 521.1k
Yi Gong	Deputy General Manager	2.8yrs	CN¥1.02m	0.014% CN¥ 1.7m
Wenfu Wang	Deputy GM & Director	4.2yrs	CN¥878.80k	0.0044% CN¥ 521.1k
Yanli Huang	Board Secretary	5.8yrs	CN¥475.50k	0.0029% CN¥ 335.2k
Haitao Chen	Deputy General Manager	5.3yrs	CN¥839.30k	0.0044% CN¥ 521.1k
Guangsheng Wang	Deputy General Manager	5.3yrs	CN¥893.40k	0.0044% CN¥ 521.1k
Ji Zhang	Deputy General Manager	2.2yrs	CN¥1.10m	no data
Shirley Zhang	International Human Resources Director	no data	no data	no data
Jiangtao Zhang	Chief Engineer	18.6yrs	no data	no data
Peter Pedersen	President of North America	less than a year	no data	no data

5.3yrs

Average Tenure

47yo

Average Age

Experienced Management: 688139's management team is seasoned and experienced (5.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Zhanjie Liu	GM & Director	18.6yrs	CN¥2.47m	0.020% CN¥ 2.3m
Wenfu Wang	Deputy GM & Director	3.1yrs	CN¥878.80k	0.0044% CN¥ 521.1k
Yun Jie Zhou	Director	5.8yrs	no data	no data
Wenwen Gong	Director	2.8yrs	no data	no data
Jie Chen	Independent Director	5.8yrs	CN¥150.00k	no data
Weide Huang	Independent Director	5.8yrs	CN¥150.00k	no data
Xuejuan Zhang	Chairman of the Supervisory Board	2.8yrs	no data	no data
Congzhao Guo	Supervisor	5.8yrs	no data	no data
Lan Jiang	Supervisory Board Chairman	no data	no data	0.00089% CN¥ 104.7k

5.8yrs

Average Tenure

51yo

Average Age

Experienced Board: 688139's board of directors are considered experienced (5.8 years average tenure).

Qingdao Haier BiomedicalLtd Management

Management criteria checks 3/4

Key information

Recent management updates

Qingdao Haier Biomedical Co.,Ltd, Annual General Meeting, Apr 18, 2024

Less than half of directors are independent

Recent updates

Further Upside For Qingdao Haier Biomedical Co.,Ltd (SHSE:688139) Shares Could Introduce Price Risks After 33% Bounce

Further Upside For Qingdao Haier Biomedical Co.,Ltd (SHSE:688139) Shares Could Introduce Price Risks After 33% Bounce

Investor sentiment improves as stock rises 15%

Full year 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 19%

Qingdao Haier Biomedical Co.,Ltd to Report Q1, 2024 Results on Apr 26, 2024

Qingdao Haier Biomedical Co.,Ltd, Annual General Meeting, Apr 18, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 18%

Investor sentiment deteriorates as stock falls 18%

Third quarter 2023 earnings released: EPS: CN¥0.25 (vs CN¥0.51 in 3Q 2022)

Consensus EPS estimates fall by 12%

Price target decreased by 9.1% to CN¥92.50

Second quarter 2023 earnings released: EPS: CN¥0.45 (vs CN¥0.59 in 2Q 2022)

Qingdao Haier Biomedical Co., Ltd to Report First Half, 2023 Results on Aug 30, 2023

Full year 2022 earnings: EPS misses analyst expectations

Full year 2022 earnings released: EPS: CN¥1.89 (vs CN¥2.67 in FY 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.51 (vs CN¥0.39 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.59 (vs CN¥0.49 in 2Q 2021)

Investor sentiment improved over the past week

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Price target decreased to CN¥126

Price target decreased to CN¥126

Investor sentiment improved over the past week

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Qingdao Haier Biomedical Co., Ltd. (SHSE:688139) announces an Equity Buyback for CNY 100 million worth of its shares.

Third quarter 2021 earnings released: EPS CN¥0.39 (vs CN¥0.37 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.49 (vs CN¥0.27 in 2Q 2020)

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥1.32 (vs CN¥0.22 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥1.20 (vs CN¥0.73 in FY 2019)

Investor sentiment improved over the past week

Qingdao Haier Biomedical Co., Ltd. to Report Fiscal Year 2020 Results on Mar 26, 2021

New 90-day high: CN¥86.02

New 90-day high: CN¥78.90

Qingdao Haier Biomedical Co., Ltd. to Report First Half, 2020 Results on Aug 21, 2020

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age